.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,667,300

« Back to Dashboard

Details for Patent: 6,667,300

Title: Inhibitors of human phosphatidylinositol 3-kinase delta
Abstract:Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K.delta. plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K.delta., while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity. Methods of using PI3K.delta. inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K.delta. inhibitory compounds to inhibit PI3K.delta.-mediated processes in vitro and in vivo.
Inventor(s): Sadhu; Chanchal (Bothell, WA), Dick; Ken (Bothell, WA), Treiberg; Jennifer (Bothell, WA), Sowell; C. Gregory (Mukilteo, WA), Kesicki; Edward A. (Bothell, WA), Oliver; Amy (Bothell, WA)
Assignee: ICOS Corporation (Bothell, WA)
Filing Date:Oct 19, 2001
Application Number:10/027,591
Claims:1. A method of disrupting leukocyte function comprising a step of contacting leukocytes with a compound having a structure ##STR90## wherein A is an optionally substituted monocyclic 5-membered heterocyclic ring system containing two or three nitrogen atoms or a bicyclic ring system containing two nitrogen atoms and one ring of the bicyclic system is aromatic; X is selected from the group consisting of C(R.sup.b).sub.2, CH.sub.2 CHR.sup.b, and CH.dbd.C(R.sup.b); Y is selected from the group consisting of S, SO, and SO.sub.2 ; R.sup.1 and R.sup.2, independently, are selected from the group consisting of hydrogen, C.sub.1-6 alkyl, aryl, a heteroaryl, halo, NHC(.dbd.O) C.sub.1-3 alkyleneN(R.sup.a).sub.2, NO.sub.2, OR.sup.a, CF.sub.3, OCF.sub.3, N(R.sup.a).sub.2, CN, OC(.dbd.O)R.sup.a, C(.dbd.O)R.sup.a, C(.dbd.O)OR.sup.a, arylOR.sup.b, Het, NR.sup.a C(.dbd.O)C.sub.1-3 alkyleneC(.dbd.O)OR.sup.a, C(.dbd.O)OR.sup.a, C.sub.1-3 alkyleneN(R.sup.a).sub.2, arylOC(.dbd.O)R.sup.a, C.sub.1-4 alkyleneC(.dbd.O)OR.sup.a, OC.sub.1-4 alkyleneC (.dbd.0) OR.sup.a, C.sub.1-4 alkyleneOC.sub.1-4 alkyleneC(.dbd.O)--OR.sup.a, C(.dbd.O)NR.sup.a SO.sub.2 R.sup.a, C.sub.1-4 alkyleneN(R.sup.a).sub.2, C.sub.2-6 alkenylene-N(R.sup.a).sub.2, C(.dbd.O)NR.sup.a C.sub.1-4 alkyleneOR.sup.a C(.dbd.O)NR.sup.a C.sub.1-4 alkylene-Het, OC.sub.2-4 alkyleneN(R.sup.a).sub.2, OC.sub.1-4 alkyleneCH(OR.sup.b)CH.sub.2 N(R.sup.a).sub.2, OC.sub.1-4 alkyleneHet, OC.sub.2-4 alkyleneOR.sup.a, OC.sub.2-4 alkylene-NR.sup.a C(.dbd.O)OR.sup.a, NR.sup.a C.sub.1-4 alkyleneN(R.sup.a).sub.2, NR.sup.a C(.dbd.O)R.sup.a, NR.sup.a C (.dbd.O)N(R.sup.a).sub.2, N(SO.sub.2 C.sub.1-4 alkyl).sub.2, NR.sup.a C(SO.sub.2 C.sub.1-4 alkyl), SO.sub.2 N(R.sup.a).sub.2, OSO.sub.2 CF.sub.3, C.sub.1-3 alkylenearyl, C.sub.1-4 alkyleneHet, b C.sub.1-6 alkyleneOR.sup.b, C.sub.1-3 alkyleneN(R.sup.a).sub.2, C(.dbd.O)N(R.sup.a).sub.2, NHC(.dbd.O)C.sub.1 -C.sub.3 alkylenearyl, C.sub.3-8 cycloalkyl, C.sub.3-8 hetero-cycloalkyl, arylOC.sub.1-3 alkyleneN(R.sup.a).sub.2, arylOC(.dbd.O)R.sup.b, NHC(.dbd.O)C.sub.1-3 alkyleneC.sub.3-8 heterocycloalkyl, NHC(.dbd.O)--C.sub.1-3 alkyleneHet, OC.sub.1-4 alkyleneOC.sub.1-4 alkyleneC(.dbd.O)OR C(.dbd.O) C.sub.1-4 alkyleneHet, and NHC (.dbd.O)haloC.sub.1-6 alkyl; R.sup.3 is optionally substituted aryl; R.sup.a is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sup.3-8 cycloalkyl, C.sub.3-8 heterocyclo-alkyl, C.sub.1-3 alkyleneN(R.sup.c).sub.2, aryl, arylC.sub.1-3 alkyl, C.sub.1-3 alkylenearyl, heteroaryl, heteroarylC.sub.1-3 alkyl, and C.sub.1-3 alkyleneheteroaryl; or two R.sup.a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom; R.sup.b is selected from the group consisting of hydrogen, C.sub.1-6 alkyl; R.sup.c is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, aryl, and hetero-aryl; Het is selected from the group consisting of 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, pyrroline, 2H-pyran, 4H-pyran, morpholine, thio-morpholine, piperidine, 1,4-dithiane, and 1,4-dioxane, and optionally substituted with C.sub.1-4 alkyl or C(.dbd.O)OR.sup.a ; and pharmaceutically acceptable salts or solvates, in an amount sufficient to inhibit phosphatidylinositol 3-kinase delta activity in said leukocytes.

2. A method of inhibiting kinase activity of a phosphatidylinositol 3-kinase delta polypeptide comprising a step of contacting the polypeptide with a compound having a structure ##STR91## wherein A is an optionally substituted monocyclic 5-membered heterocyclic ring system containing two or three nitrogen atoms or a bicyclic ring system containing two nitrogen atoms and one ring of the bicyclic system is aromatic; X is selected from the group consisting of C(R.sup.b).sub.2, CH.sub.2 CHR.sup.b, and CH.dbd.C(R.sup.b); Y is selected from the group consisting of S, SO, and SO.sub.2 ; R.sup.1 and R.sup.2, independently, are selected from the group consisting of hydrogen, C.sub.1-6 alkyl, aryl, heteroaryl, halo, NHC(.dbd.O)C.sub.1-3 alkyleneN(R.sup.a).sub.2, NO.sub.2, OR.sup.a, CF.sub.3, OCF.sub.3, N(R.sup.a).sub.2, CN, OC(.dbd.O)R.sup.a, C(.dbd.O)R.sup.a, C(.dbd.O)OR.sup.a, arylOR.sup.b, Het, NR.sup.a C(.dbd.O)C.sub.1-3 alkylenec(.dbd.O)OR.sup.a, arylO-C.sub.1-3 alkyleneN(R.sup.a).sub.2, arylOC(.dbd.O)R.sup.a, C.sub.1-4 alkyleneC(.dbd.O)OR.sup.a, OC.sub.1-4 alkyleneC(.dbd.O)OR.sup.a, C.sub.1-4 alkyleneOC.sub.1-4 alkyleneC(.dbd.O)--OR.sup.a, C (.dbd.O)NR.sup.a SO.sub.2 R.sup.a, C.sub.1-4 alkyleneN(R.sup.a).sub.2, C.sub.2-6 alkenylene-N(R.sup.a).sub.2, C(.dbd.O)NR.sup.a C.sub.1-4 alkyleneOR.sup.a, C(.dbd.O)NR.sup.a C.sub.1-4 alkyleneHet, OC.sub.2-4 alkyleneN(R.sup.a).sub.2, OC.sub.1-4 alkyleneCH(OR.sup.b)CH.sub.2 N(R.sup.a).sub.2, OC.sub.1-4 alkyleneHet, OC.sub.2-4 alkyleneOR.sup.a, OC.sub.2-4 alkylene-NR.sup.a C(.dbd.O)OR.sup.a, NR.sup.a C.sub.1-4 alkyleneN(R.sup.a).sub.2, NR.sup.a C(.dbd.O)R.sup.a, NR.sup.a C (.dbd.O)N(R.sup.a) 2' N(SO.sub.2 C.sub.1-4 alkyl).sub.2, NR.sup.a (SO.sub.2 C.sub.1-4 alkyl), SO.sub.2 N(R.sup.a).sub.2, OSO.sub.2 CF.sub.3, C.sub.1-3 alkylenearyl, C.sub.1-4 alkyleneHet, C.sub.1-6 alkyleneOR.sup.b, C.sub.1-3 alkyleneN(R.sup.a).sub.2, C(.dbd.O)N(R.sup.a).sub.2, NHC(.dbd.O)C.sub.1 -C.sub.3 alkylenearyl, C.sub.3-8 cycloalkyl, C.sub.3-8 heterocycloalkyl, aryloC.sub.1-3 alkyleneN(R.sup.a).sub.2, arylOC(.dbd.O)R.sup.b, NHC(.dbd.O)C.sub.1-3 alkyleneC.sub.3-8 heterocycloalkyl, NHC (.dbd.O)--C.sub.1-3 alkyleneHet, OC.sub.1-4 alkyleneOC.sub.1-4 alkyleneC(.dbd.O)OR.sup.b, C(.dbd.O)C.sub.1-4 alkyleneHet, and NHC(.dbd.O)haloC.sub.1-6 alkyl; R.sup.3 is optionally substituted; R.sup.a is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 heterocycloalkyl, C.sub.1-3 alkyleneN(R.sup.c).sub.2, aryl, arylC.sub.1-3 alkyl, C.sub.1-3 alkylenearyl, heteroaryl, heteroarylC.sub.1-3 alkyl, and C.sub.1-3 alkyleneheteroaryl; or two R.sup.a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom; R.sup.b is selected from the group consisting of hydrogen, C.sub.1-6 alkyl; R.sup.c is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, aryl, and heteroaryl; Het is selected from the group consisting of 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, pyrroline, 2H-pyran, 4H-pyran, morpholine, thiomorpholine, piperidine, 1,4-dithiane, and 1,4-dioxane, and optionally substituted with C.sub.1-4 alkyl or C(.dbd.O)OR.sup.a ; and pharmaceutically acceptable salts or solvates thereof.

3. A compound having a general structural formula ##STR92## wherein A is an optionally substituted monocyclic 5-membered heterocyclic ring system containing two or three nitrogen atoms or a bicyclic ring system containing two nitrogen atoms and one ring of the cyclic system is aromatic; X is selected from the group consisting of b CH.sub.2 CHR.sup.b and CH.dbd.C(R.sup.b); Y is selected from the group consisting of S, SO, and SO.sub.2 ; R.sup.1 and R.sup.2, independently, are selected from the group consisting of hydrogen, C.sub.1-6 alkyl, aryl, heteroaryl, halo, NHC(.dbd.O)C.sub.1-3 alkyleneN(R.sup.a).sub.2, NO.sub.2, OR.sup.a, CF.sub.3, OCF.sub.3, N(R.sup.a).sub.2, CN, OC(.dbd.O)R.sup.a, C(.dbd.O)R.sup.a, C(.dbd.O)OR.sup.a, arylOR.sup.b, Het, NR.sup.a C(.dbd.O)C.sub.1-3 alkyleneC(.dbd.O)OR.sup.a, arylO-C.sub.1-3 alkyleneN(R.sup.a).sub.2, arylOC(.dbd.O)R.sup.a, C.sub.1-4 alkyleneC(.dbd.O)OR.sup.a, OC.sub.1-4 alkyleneC(.dbd.O)OR.sup.a, C.sub.1-4 alkyleneOC.sub.1-4 alkyleneC(.dbd.O)--OR.sup.a, C(.dbd.O)NR.sup.a SO.sub.2 R.sup.a, C.sub.1-4 alkyleneN(R.sup.a).sub.2, C.sub.2-6 alkenylene-N(R.sup.a).sub.2, C(.dbd.O)NR.sup.a C.sub.1-4 alkyleneOR.sup.a, C(.dbd.O)NR.sup.a C.sub.1-4 alkylene-Het, OC.sub.2-4 alkyleneN(R.sup.a).sub.2, OC.sub.1-4 alkyleneCH(OR.sup.b)CH.sub.2 N(R.sup.a).sub.2, OC.sub.1-4 alkyleneHet, OC.sub.2-4 alkyleneOR.sup.a, OC.sub.2-4 alkylene-NR.sup.a C(.dbd.O)OR.sup.a, NR.sup.a C.sub.1-4 alkyleneN(R.sup.a).sub.2, NR.sup.a C(.dbd.O)R.sup.a, NR.sup.a C (.dbd.O) N (R.sup.a).sub.2, N(SO.sub.2 C.sub.1-4 alkyl).sub.2, NR.sup.a (SO.sub.2 C.sub.1-4 alkyl), SO.sub.2 N(R.sup.a).sub.2, OSO.sub.2 CF.sub.3, C.sub.1-3 alkylenearyl, C.sub.1-4 alkyleneHet, C.sub.1-6 alkyleneOR.sup.b, C.sub.1-3 alkyleneN(R.sup.a).sub.2, C(.dbd.O)N(R.sup.a).sub.2, NHC-(.dbd.O) C.sub.1 -C.sub.3 alkylenearyl, C.sub.3-8 cycloalkyl, C.sub.3-8 heterocycloalkyl, arylOC.sub.1-3 alkyleneN(R.sup.a).sub.2, arylOC(.dbd.O)R.sup.b, NHC(.dbd.O)--C.sub.1-3 alkyleneC.sub.3-8 heterocycloalkyl, NHC(.dbd.O)C.sub.1-3 alkyleneHet, OC.sub.1-4 alkyleneOC.sub.1-4 alkyleneC(.dbd.O) OR.sup.b, C (.dbd.O)C.sub.1-4 alkyleneHet, and NHC (.dbd.O) haloC.sub.1-6 alkyl; R.sup.3 is optionally substituted aryl; R.sup.a is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 heterocycloalkyl, C.sub.1-3 alkyleneN(R.sup.c).sub.2, aryl, arylC.sub.1-3 alkyl, C.sub.1-3 alkylenearyl, heteroaryl, heteroarylC.sub.1-3 alkyl, and C.sub.1-3 alkyleneheteroaryl; or two R.sup.a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom; R.sup.b is selected from the group consisting of hydrogen, C.sub.1-6 alkyl; R.sup.c is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, aryl, and heteroaryl; Het is selected from the group consisting of 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, pyrroline, 2H-pyran, 4H-pyran, morpholine, thiomorpholine, piperidine, 1,4-dithiane, and 1,4-dioxane, and optionally substituted with C.sub.1-4 alkyl or C(.dbd.O)OR.sup.a ; and pharmaceutically acceptable salts or solvates thereof.

4. The compound of claim 3 wherein X is selected from the group consisting of CH.sub.2 CH.sub.2, CH.dbd.CH, CH(CH.sub.2 CH.sub.3), and CH.sub.2 CH(CH.sub.3).

5. The compound of claim 3 wherein Y is.

6. The compound of claim 3 wherein the A ring system is selected from the group consisting of ##STR93##

7. The compound of claim 6 wherein the A ring system is substituted with one to three substituents selected from the group consisting of N(R.sup.a).sub.2, halo, C.sub.1-3 alkyl, S(C.sub.1-3 alkyl), OR.sup.a, and ##STR94##

8. The compound of claim 7 wherein the A ring system is substituted with one to three substituents selected from the group consisting of NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2, NHCH.sub.2 C.sub.6 H.sub.5, NH(C.sub.2 H.sub.5), Cl, F, CH.sub.3, SCH.sub.3, OH, and ##STR95##

9. The compound of claim 4 wherein R.sup.1 and R.sup.2, independently, are selected from the group consisting of hydrogen, OR.sup.a, halo, C.sub.1-6 alkyl, CF.sub.3, NO.sub.2, N(R.sup.a).sub.2, NR.sup.a C.sub.1-3 alkyleneN(R.sup.a).sub.2, and OC.sub.1-3 alkyleneOR.sup.a ; specific substituents include, but are not limited to, H, OCH.sub.3, Cl, Br, F, CH.sub.3, CE.sub.3, NO.sub.2, OH, N(CH.sub.3).sub.2, ##STR96## and O(CH.sub.2).sub.2 OCH.sub.2 C.sub.6 H.sub.5.

10. The compound of claim 4 wherein R.sup.3 is ##STR97##

11. The compound of claim 3 wherein R.sup.3 is substituted with a substituent selected from the group consisting of halo, OR.sup.a, C.sub.1-6 alkyl, aryl, heteroaryl, NO.sub.2, N(R.sup.a).sub.2, NR.sup.a SO.sub.2 CF.sub.3, NR.sup.a C(.dbd.O)R.sup.a, C(.dbd.O)OR.sup.a, SO.sub.2 N(R.sup.a).sub.2, CN, C(.dbd.O)R.sup.a, C.sub.1-4 alkyleneN(R.sup.a).sub.2, OC.sub.1-4 alkyleneC.ident.CR.sup.a, OC.sub.1-4 alkyleneC(.dbd.O)N(R.sup.a).sub.2, OC.sub.1-4 alkylenearyl, OC.sub.1-4 alkyleneheteroaryl, OC.sub.1-4 alkyleneHet, OC.sub.1-4 alkyleneN(R.sup.a).sub.2, and N(R.sup.a)C.sub.1-4 alkyleneN(R.sup.a).sub.2.

12. The compound of claim 3 wherein R.sup.3 is substituted with a substituent selected from the group consisting of Cl, F, CH.sub.3, CH(CH.sub.3).sub.2, OH, OCH.sub.3, OCH.sub.2 C.sub.6 H.sub.5, O(CH.sub.2).sub.3 N(CH.sub.3).sub.2, OCH.sub.2 C.ident.CH, OCH.sub.2 C(.dbd.O)--NH.sub.2, C.sub.6 H.sub.5, NO.sub.2, NH.sub.2, NHC(.dbd.O)CH.sub.3, CO.sub.2 H, and N(CH.sub.3)--CH.sub.2 CH.sub.2 N(CH.sub.3).sub.2, and ##STR98##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc